Free Trial

Alkermes (ALKS) Competitors

Alkermes logo
$29.36 +0.16 (+0.55%)
Closing price 04:00 PM Eastern
Extended Trading
$29.37 +0.01 (+0.03%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALKS vs. ABEO, MEDP, OMCL, AMN, BIIB, UTHR, INCY, NBIX, EXEL, and BMRN

Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector.

Alkermes vs. Its Competitors

Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Abeona Therapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abeona Therapeutics$3.50M96.91-$63.73M-$1.27-5.22
Alkermes$1.51B3.20$367.07M$2.0914.05

Alkermes has a net margin of 23.30% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 27.52% beat Abeona Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Abeona TherapeuticsN/A -118.82% -52.48%
Alkermes 23.30%27.52%17.98%

Abeona Therapeutics presently has a consensus target price of $19.25, indicating a potential upside of 190.35%. Alkermes has a consensus target price of $40.92, indicating a potential upside of 39.36%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alkermes
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83

In the previous week, Abeona Therapeutics had 9 more articles in the media than Alkermes. MarketBeat recorded 22 mentions for Abeona Therapeutics and 13 mentions for Alkermes. Alkermes' average media sentiment score of 0.86 beat Abeona Therapeutics' score of 0.20 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
7 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alkermes
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Alkermes beats Abeona Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALKS vs. The Competition

MetricAlkermesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.84B$2.93B$5.50B$9.39B
Dividend YieldN/A2.46%4.25%4.09%
P/E Ratio14.0520.3128.1019.86
Price / Sales3.20261.57402.2879.25
Price / Cash10.8842.3835.5357.53
Price / Book3.247.838.265.72
Net Income$367.07M-$55.11M$3.24B$257.80M
7 Day Performance-3.61%2.18%0.50%1.06%
1 Month Performance-1.38%12.98%7.99%11.30%
1 Year Performance19.30%1.98%28.68%17.00%

Alkermes Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALKS
Alkermes
4.7987 of 5 stars
$29.36
+0.5%
$40.92
+39.4%
+18.7%$4.84B$1.51B14.051,800Analyst Forecast
ABEO
Abeona Therapeutics
3.7436 of 5 stars
$5.75
-2.4%
$19.25
+234.8%
+17.2%$294.17M$3.50M-4.5390Analyst Forecast
MEDP
Medpace
3.756 of 5 stars
$318.90
-0.8%
$344.82
+8.1%
-31.2%$9.17B$2.11B24.345,900Upcoming Earnings
OMCL
Omnicell
3.4149 of 5 stars
$28.92
-3.1%
$44.83
+55.0%
+0.8%$1.35B$1.11B62.873,670News Coverage
Analyst Revision
AMN
AMN Healthcare Services
4.3681 of 5 stars
$21.23
-3.1%
$32.08
+51.1%
-65.0%$812.68M$2.98B-4.902,968Analyst Revision
BIIB
Biogen
4.9034 of 5 stars
$130.13
-2.1%
$188.48
+44.8%
-42.9%$19.07B$9.68B12.857,605Trending News
Insider Trade
Analyst Revision
UTHR
United Therapeutics
4.9873 of 5 stars
$290.39
-1.4%
$386.15
+33.0%
-9.2%$13.10B$2.88B11.591,305Positive News
Insider Trade
INCY
Incyte
4.622 of 5 stars
$67.27
-1.7%
$74.53
+10.8%
+8.2%$13.02B$4.24B210.232,617Trending News
Analyst Forecast
Insider Trade
Analyst Revision
NBIX
Neurocrine Biosciences
4.4941 of 5 stars
$127.88
-1.0%
$162.00
+26.7%
-9.5%$12.66B$2.36B43.351,800Trending News
Analyst Revision
EXEL
Exelixis
4.7739 of 5 stars
$44.16
-4.3%
$43.56
-1.4%
+96.9%$12.04B$2.17B20.071,147Analyst Forecast
BMRN
BioMarin Pharmaceutical
4.9888 of 5 stars
$57.41
-0.2%
$93.61
+63.1%
-32.0%$11.01B$2.85B21.343,040News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ALKS) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners